Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schaapveld

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
Genes, Chromosomes & Cancer|February 25, 2005
A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instabilityJantine L Westra, Ludolf G Boven, Pieter van der Vlies, et al.
Cancer Medicine|September 20, 2022
Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohortDelal Akdeniz, Iris Kramer, Carolien H M van Deurzen, et al.
Journal of Cancer Survivorship : Research and Practice|January 15, 2019
Factors associated with an adverse work outcome in breast cancer survivors 5-10 years after diagnosis: a cross-sectional studySietske J Tamminga, Pieter Coenen, Carmen Paalman, et al.
International Journal of Surgery (London, England)|April 10, 2023
Surgical outcomes following breast reconstruction in patients with and without a history of chest radiotherapy for Hodgkin lymphoma: a multicentre, matched cohort studyJ Xavier Harmeling, Leonie A E Woerdeman, Ezgi Ozdemir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patientsJantine L Westra, Michael Schaapveld, Harry Hollema, et al.
Breast Cancer Research and Treatment|September 23, 2020
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort studyJudy N Jacobse, Michael Schaapveld, Naomi B Boekel, et al.
Breast Cancer Research and Treatment|May 4, 2021
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancerEmma J Groen, Marieke E M van der Noordaa, Michael Schaapveld, et al.
Plos One|July 25, 2022
Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancerLisanne S Rigter, Petur Snaebjornsson, Efraim H Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin LymphomaFrederika A van Nimwegen, Michael Schaapveld, David J Cutter, et al.
British Journal of Cancer|January 31, 2018
High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivorsSimone de Vries, Michael Schaapveld, Frederika A van Nimwegen, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
Genes, Chromosomes & Cancer|February 25, 2005
A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instabilityJantine L Westra, Ludolf G Boven, Pieter van der Vlies, et al.
Cancer Medicine|September 20, 2022
Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: Results from a nationwide cohortDelal Akdeniz, Iris Kramer, Carolien H M van Deurzen, et al.
Journal of Cancer Survivorship : Research and Practice|January 15, 2019
Factors associated with an adverse work outcome in breast cancer survivors 5-10 years after diagnosis: a cross-sectional studySietske J Tamminga, Pieter Coenen, Carmen Paalman, et al.
International Journal of Surgery (London, England)|April 10, 2023
Surgical outcomes following breast reconstruction in patients with and without a history of chest radiotherapy for Hodgkin lymphoma: a multicentre, matched cohort studyJ Xavier Harmeling, Leonie A E Woerdeman, Ezgi Ozdemir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patientsJantine L Westra, Michael Schaapveld, Harry Hollema, et al.
Breast Cancer Research and Treatment|September 23, 2020
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort studyJudy N Jacobse, Michael Schaapveld, Naomi B Boekel, et al.
Breast Cancer Research and Treatment|May 4, 2021
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancerEmma J Groen, Marieke E M van der Noordaa, Michael Schaapveld, et al.
Plos One|July 25, 2022
Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancerLisanne S Rigter, Petur Snaebjornsson, Efraim H Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin LymphomaFrederika A van Nimwegen, Michael Schaapveld, David J Cutter, et al.
British Journal of Cancer|January 31, 2018
High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivorsSimone de Vries, Michael Schaapveld, Frederika A van Nimwegen, et al.
Pageof 14